Immunogenici-T

Serious side effects from medications are still a major cause of death. Some of the most dangerous – and hardest to predict – are triggered by T-cells, a key part of the immune system. At present, drug companies don’t have reliable ways to test whether a new drug might set off this kind of immune reaction in patients. We’re developing a new testing approach to more accurately predict whether a drug is likely to activate T-cells in harmful ways.

This method could help companies identify safer drug candidates earlier in development, potentially saving lives and reducing the high costs of late-stage drug failures, which can reach up to $1 billion.

Want to learn more or chat with the team? Reach out to Immunogenici-T’s team leader, Andrew Gibson via a.gibson@iiid.murdoch.edu.au

If you would like an introduction – we’re here to help! Contact the ON team via on@csiro.au